Miami University
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Donor plasmid vectors (US 11,674,157) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Non-invasive diagnostic systems and methods for using the same (US 11,714,114) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells (US 9,233,119) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,534,947 | Oboe reed gouge apparatus In force · From the USPTO record | In force | From the USPTO record | |
| US 7,669,364 | Devices, kits, and methods for providing protection to plants In force · From the USPTO record | In force | From the USPTO record | |
| US 8,455,191 | Cell transdifferentiation into brown adipocytes In force · From the USPTO record | In force | From the USPTO record | |
| US 8,835,112 | Cell transdifferentiation into brown adipocytes In force · From the USPTO record | In force | From the USPTO record | |
| US 8,808,324 | Hand pressure device to diminish gag reflex response In force · From the USPTO record | In force | From the USPTO record | |
| US 8,432,249 | Advanced transitional cup In force · From the USPTO record | In force | From the USPTO record | |
| US 9,492,470 | Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,233,119 | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,909,106 | Recombinant baculovirus expression vector and cell In force · From the USPTO record | In force | From the USPTO record | |
| US 10,813,957 | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 8 lapsed for an unpaid fee · 18 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 2 abandoned · 10 no status recorded